Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $56.35 USD
Change Today -0.02 / -0.04%
Volume 17.9M
MYL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Munich
As of 8:10 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

mylan nv (MYL) Snapshot

Open
$56.74
Previous Close
$56.37
Day High
$57.00
Day Low
$53.81
52 Week High
04/24/15 - $76.69
52 Week Low
08/13/14 - $44.80
Market Cap
27.7B
Average Volume 10 Days
9.6M
EPS TTM
$2.95
Shares Outstanding
491.5M
EX-Date
07/17/07
P/E TM
19.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for MYLAN NV (MYL)

mylan nv (MYL) Details

Mylan N.V., through its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and the manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular therapeutic areas. In addition, the company produces finished dosage form (FDF) products for the antiretroviral (ARV) market and non-ARV FDF products that are marketed to third parties. It offers generic pharmaceutical products to proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. Further, the company manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. It sells specialty pharmaceuticals to pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan N.V. was founded in 1961 and is headquartered in Potters Bar, Hertfordshire.

25,000 Employees
Last Reported Date: 03/2/15
Founded in 1961

mylan nv (MYL) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: $1.2M
President, Executive Director and Member of S...
Total Annual Compensation: $890.4K
Executive Chairman and Chairman of Executive ...
Total Annual Compensation: $1.4M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $650.0K
President of Mylan North America
Total Annual Compensation: $545.2K
Compensation as of Fiscal Year 2014.

mylan nv (MYL) Key Developments

Mylan N.V. Launches Generic Version of Namenda® Tablets

Mylan N.V. announced the U.S. launch of Memantine Hydrochloride Tablets USP, 5 mg and 10 mg, which is the generic version of Forest's Namenda® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of moderate to severe dementia of the Alzheimer's type. Memantine Hydrochloride Tablets USP, 5 mg and 10 mg, had U.S. sales of approximately $1.4 billion for the 12 months ending March 31, 2015.

Mylan N.V. Launches First Generic Targretin® Capsules

Mylan N.V. announced the U.S. launch of Bexarotene 75mg Capsules, which is the generic version of Valeant's Targretin® Capsules. This product is indicated for the treatment of cutaneous manifestations of cutaneous t-cell lymphoma in patients who are refractory to at least one prior systemic therapy.

Pulmatrix, Inc. Enters into ex-US Development Agreement with Mylan N.V

Pulmatrix Inc. announced that it has entered into an ex-US development agreement with Mylan N.V. for the treatment of chronic obstructive pulmonary disease, or COPD. The agreement is for PUR0200, a clinical stage bronchodilator therapy being studied for chronic obstructive pulmonary disease (COPD) and the first small molecule formulation from the company's novel iSPERSE inhaled dry powder technology. PUR0200 contains a long-acting muscarinic agent (LAMA) being studied for the treatment of COPD and current clinical development is focused on pharmacokinetic bioequivalence in Europe. Under the terms of the agreement, Pulmatrix will lead the development work and pharmacokinetic clinical study with collaborative support from Mylan.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYL:US $56.35 USD -0.02

MYL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,932 JPY +4.00
Becton Dickinson and Co $149.88 USD +3.55
Perrigo Co PLC $192.07 USD -1.53
Sun Pharmaceutical Industries Ltd 821.70 INR +1.55
WW Grainger Inc $225.95 USD +0.08
View Industry Companies
 

Industry Analysis

MYL

Industry Average

Valuation MYL Industry Range
Price/Earnings 26.5x
Price/Sales 3.0x
Price/Book 3.0x
Price/Cash Flow 31.7x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYLAN NV, please visit www.mylan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.